Eczema Clinical Trial
Official title:
A Multi-Center Clinical Trial to Evaluate the Efficacy of an Over-the-Counter Cream in the Management of Mild to Moderate Atopic Dermatitis in Infants and Toddlers
This study is for infants with mild to moderate dry and itchy skin. This study will involve
going to the doctor for 6 visits over 2 weeks. All participants' skin will be examined by a
dermatologist to determine if they have atopic dermatitis and have an active mild to
moderate eczema wound. Participant's parents/guardians will be asked a few questions to
determine if their child qualifies for the study.
Then all participants' caregivers will complete a questionnaire at the beginning of the
study. The child's skin will be examined to rate the level of their eczema and a trained
examiner will grade the looks and symptoms of their eczema. All parents or guardians will be
instructed how to apply the test product and how to record usage on a diary card and then
apply the test product. The test product will be applied at least 2 times per day or more as
needed on all body areas, including the face affected throughout the study.
One digital picture will be taken of one eczema wound. Another digital picture will be taken
of the area around this wound. These pictures will be taken on Day 0 (Baseline), Day 3, and
Day 14.
Once product is applied the skin will be examined for any adverse events and all
participants' caregivers will complete a questionnaire on study day 1, 3, 7 and 14.
This is a multi-center, two-arm clinical trial in participants aged 2 - 35 months with mild
to moderate Atopic Dermatitis (AD) as determined by the study physician. A sufficient number
of participants will be enrolled in this study to yield 40 participants who complete the
trial, 30 in the investigational product group and 10 in the active control group.
The investigational and control (EpiCeram®) products will be used topically. Participant
caregivers will be instructed to gently massage the assigned product into the participant's
skin. The treatments will be applied at least 2 times per day on all body areas, including
areas of the body and face affected by AD. No product should be applied within 4 hours of a
site visit. These treatments will be used in place of the participant's current moisturizers
and/or emollients.
Diaries will be completed by the participants' caregivers each day, beginning upon
initiation of therapy and continuing until trial completion/discontinuation, and will
include information on product application and use of rescue medication.
All participants will visit the clinical site for assessments at baseline (Day 0) and on
Days 1, 2, 3, 7 and 14. Clinical assessments include the Eczema Area and Severity index
(EASI) and Investigator's Global Atopic Dermatitis Assessment (IGADA). Instrumental
assessment of hydration will be done using a Corneometer (Courage & Khazaka, Germany).
Caregivers will also complete a questionnaire to assess product experience. The final visit
will occur on Day 14 or on the day of participant withdrawal from the trial.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01257061 -
Effectiveness of Clemastine Fumarate + Dexamethasone Compared to Dexchlorpheniramine Maleate in Eczema Treatment
|
Phase 3 | |
| Completed |
NCT03563066 -
Effect of Benralizumab in Atopic Dermatitis
|
Phase 2 | |
| Withdrawn |
NCT03089476 -
Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy
|
N/A | |
| Recruiting |
NCT04818138 -
BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort
|
N/A | |
| Recruiting |
NCT05439577 -
A Multicentre Study to Explore the Efficacy and Safety of Mucopolysaccharide Polysulfate Cream in Patients With Eczema
|
||
| Completed |
NCT02916888 -
A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists
|
N/A | |
| Completed |
NCT02075632 -
Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream
|
Phase 2 | |
| Completed |
NCT00143819 -
Neuroskin Forte for Dry Skin Relief in Eczema and Psoriasis
|
Phase 2 | |
| Recruiting |
NCT01631617 -
Effects of Treatments on Atopic Dermatitis
|
Phase 2 | |
| Completed |
NCT04358224 -
The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment
|
Phase 4 | |
| Not yet recruiting |
NCT04520308 -
An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With Atopic Dermatitis
|
Phase 4 | |
| Recruiting |
NCT03340155 -
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
|
N/A | |
| Completed |
NCT04023084 -
Response of Children With Atopic Dermatitis (Eczema) to Eucrisa
|
Phase 4 | |
| Completed |
NCT03720470 -
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
|
Phase 3 | |
| Completed |
NCT05583019 -
Atopic Dermatitis With Accelerometry and Polysomnography (ADAP)
|
||
| Completed |
NCT03293030 -
Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis
|
Phase 4 | |
| Completed |
NCT02002871 -
Blue Light for Treating Eczema
|
N/A | |
| Completed |
NCT01420705 -
Bacille Calmette-Guérin (BCG) Vaccine and Atopy
|
N/A | |
| Recruiting |
NCT01012453 -
A Randomised Clinical Trial in a Population of Health Care Workers With Hand Eczema
|
N/A | |
| Completed |
NCT00375713 -
Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema
|
Phase 3 |